TTD moves to cut surgery wait time at BIRRD hospital
TTD chairman BR Naidu, along with Executive Officer J Syamala Rao, conducted a detailed review of various administrative aspects of BIRRD on Wednesday.
On this occasion, Naidu remarked that BIRRD had earned a global reputation over the years but had seen a decline in performance in recent times. He called for concerted efforts to bring the hospital back to its past prominence.
He emphasised that priority should be given to providing quality medical services to farmers and the economically weaker sections from rural areas. To reduce the waiting period for surgeries, particularly for joint replacements, the chairman stressed the need to enhance infrastructure and ensure the availability of essential resources including specialist doctors, support staff, medicines, and surgical equipment.
Naidu also suggested that the imported equipment used in procedures such as knee replacements should be of high quality and procured at prices aligned with Indian market standards.
Executive officer Syamala Rao said that just as the 'Aapanna Hrudaya Scheme' has enabled donors to support paediatric heart surgeries at Sri Padmavathi Children's Heart Centre, a similar initiative should be explored at BIRRD.
He directed the JEO, financial advisor and chief accounts officer, and the BIRRD director to jointly prepare a report on mobilising donor contributions to support surgeries for the underprivileged. He also underscored the importance of making the hospital accessible to all and advised that advanced medical equipment be procured in line with regulatory norms.
BIRRD director Dr G Jagadeesh explained that while surgeries for differently-abled children are being performed promptly, joint replacement procedures currently involve a waiting period of nearly one year. He gave a comprehensive presentation outlining the initiatives and progress made by the hospital since its inception.
TTD Board Members Nannapaneni Sadasiva Rao, T Janaki Devi, Dr Adit Desai, JEO V Veerabrahmam, FA & CAO O Balaji, and other officials took part in the meeting.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
an hour ago
- Time of India
S&R, Saraf guide IHH's Fortis-Gleneagles hospital management tie-up in evolving Indian healthcare market
Advt By , ETLegalWorld Join the community of 2M+ industry professionals. Subscribe to Newsletter to get latest insights & analysis in your inbox. All about ETLegalWorld industry right on your smartphone! Download the ETLegalWorld App and get the Realtime updates and Save your favourite articles. S&R Associates represented Malaysia-headquartered IHH Healthcare Berhad , in the strategic collaboration between its Indian subsidiaries Fortis Healthcare Limited and Gleneagles Healthcare India , pursuant to which Fortis will manage the operations of five hospitals in the Gleneagles India network under an operation and maintenance services agreement. Saraf and Partners advised Fortis on the transaction reflects broader sectoral trends driving India's healthcare M&A activity , which saw deal volumes surge in H1 2025 despite a slight dip in total value. Private players are planning significant bed additions with a capital outlay of approximately INR 32,500 crore over five years, with particular focus on tier-2 and tier-3 city expansion and single-specialty hospitals in oncology, nephrology, and collaboration leverages IHH Healthcare Berhad's global integrated healthcare expertise with Fortis's established Indian market presence, positioning both entities to capitalize on India's expanding healthcare demand. The deal aligns with the domestic hospital sector's leadership in healthcare deal activity, as operators seek operational efficiencies and geographic expansion.S&R Associates' team was led by partners Rajat Sethi and Raya Hazarika, along with associate Stuti Dhundia. Head of competition practice Simran Dhir, partner Akshat Kulshrestha and associates Prerana De, Sehaj Mahajan and Ritik Mohapatra provided competition law advisory. Partner Niti Dixit advised on litigation transaction team led by senior partner Vaibhav Kakkar, partners Sahil Arora and Debarpan Ghosh. Partner Akshayy S Nanda's competition team assisted with regulatory compliance matters.
&w=3840&q=100)
Business Standard
an hour ago
- Business Standard
Rehab to ~25L cover: Find out how insured our athletes are against injuries
A career in sports could be financially rewarding. Medals and accompanying fame also add to the lure, nudging youngsters to take that leap. But there are pitfalls too, as injuries have cut short or reduced the career of many promising as well as established athletes worldwide. For many Indian athletes, especially those from modest backgrounds, a single accident can derail years of hard work and jeopardise their financial future. Medical bills pile up quickly, and the uncertainty of recovery can push families into debt. To provide athletes some cushion against such uncertainties, the government has rolled out several insurance and welfare initiatives. These government-backed schemes not just offer treatment, but provide financial cushioning to athletes, ensuring their focus remains on performance rather than the cost of recovery. Key national-level insurance schemes The Sports Authority of India (SAI) and the Ministry of Youth Affairs and Sports run multiple programmes that cover treatment and insurance for injuries: Pandit Deendayal Upadhyay National Welfare Programme: Provides up to ~10,00,000 for medical treatment to current and retired athletes or their families. This direct financial assistance plays a vital role in post-injury recovery. SAI Medical Insurance Schemes: Covers over 13,000 athletes, coaches and staff. Includes ~500,000 for general medical treatment and an additional ~25,00,000 for accidental death or severe injury. National Centre of Sports Sciences and Research (NCSSR): Offers specialised and subsidised treatment, injury management, and rehabilitation to athletes involved in national programmes, significantly reducing out-of-pocket healthcare costs. Central Athlete Injury Management System (CAIMS): Strengthens medical infrastructure, providing subsidised or free access to treatment facilities, indirectly relieving athletes from financial stress. State initiatives add more protection Several states are bolstering this ecosystem with their own athlete insurance policies: -Haryana offers a medical insurance cover of ~20,00,000 lakh for sportspersons. -Rajasthan's Mukhyamantri Sportsperson Beema Yojana provides ~10,00,000 cover and a ~20,000 monthly pension. What it means for athletes Reduced expenses: Access to government-funded treatment saves lakhs in private medical bills. Focused career building: With medical risks covered, athletes can train without financial anxiety. Caveats and the way forward However, there are gaps. These schemes mainly cover national-level athletes. Those at grassroots or in informal training systems remain uninsured. Awareness is another issue, athletes from rural areas often don't know such benefits exist.
Mint
an hour ago
- Mint
New IPO: NephroPlus files papers with Sebi for ₹353.4 crore IPO to expand Dialysis clinics
Nephrocare Health Services Limited, widely recognized under the brand name NephroPlus, has filed a Draft Red Herring Prospectus (DRHP) with the Securities and Exchange Board of India (SEBI) to raise ₹ 353.4 crore through an initial public offering (IPO). The Hyderabad-based company plans to use the proceeds to expand its network of dialysis clinics across India and repay outstanding debt, with the balance allocated to general corporate purposes. The IPO will include a fresh issue of equity shares worth ₹ 353.4 crore and an offer-for-sale (OFS) of up to 1.27 crore equity shares by promoter and non-promoter shareholders. Among the OFS participants are Investcorp Private Equity Fund II, Healthcare Parent Limited, Edoras Investment Holdings Pte. Ltd., and 360 One Special Opportunities Fund. The company may also consider a pre-IPO placement of up to ₹ 70.6 crore, which would reduce the size of the fresh issue accordingly. Established in 2009, NephroPlus has emerged as Asia's largest dialysis services provider and the fifth-largest globally in terms of the number of treatments performed in FY25, according to a Frost & Sullivan report. As of now, the company operates 447 clinics across 269 cities in 21 Indian states and 4 Union Territories, serving over 33,000 patients annually. NephroPlus commands more than 50 percent revenue market share in India's organised dialysis services market. NephroPlus has also made a significant push into international markets. It currently operates 34 clinics in the Philippines, 5 in Nepal, 4 in Uzbekistan, and recently entered Saudi Arabia in a bid to tap the Middle East healthcare market. The company's promoters include Vikram Vuppala, BVP Trust (Bessemer Venture Partners), and Investcorp-affiliated entities. As per the DRHP, NephroPlus will allocate ₹ 129.1 crore from the fresh issue proceeds towards setting up new dialysis clinics in India, which aligns with its strategy to grow its domestic footprint. An additional ₹ 136 crore will be used to pre-pay or repay certain existing borrowings, enhancing the company's financial flexibility and improving its balance sheet. In FY25, the company reported ₹ 755.8 crore in revenue from operations and a profit after tax of ₹ 67 crore, reflecting robust growth amid increasing demand for kidney care services. With chronic kidney disease (CKD) rising as the third fastest-growing cause of death globally, and diabetes and hypertension being its primary drivers, NephroPlus is well-positioned to benefit from secular health trends. ICICI Securities, Ambit Private Limited, IIFL Capital Services, and Nomura Financial Advisory and Securities (India) are acting as Book Running Lead Managers (BRLMs) for the IPO. Disclaimer: The views and recommendations made above are those of individual analysts or broking companies, and not of Mint. We advise investors to check with certified experts before making any investment decisions.
